Halda Therapeutics
Halda Therapeutics, LLC (Branford, CT) Halda is pursuing biological drug development based on the research and ideas of Craig Crews, Yale professor and founder of Arvinas (NASDAQ: ARVN) and co-founder of Proteolix (developer of Kyprolis®, sold to Onyx, which was acquired by Amgen). Elm Street Ventures participated in the Series A financing in early 2019 led by Canaan Partners and the Series B financing in 2022 led by Access Industries. Other investors include WuXi, 6 Dimensions, and Connecticut Innovations. Rob Bettigole is the board observer for ESV.